论文部分内容阅读
目的调查恶性血液病患者真菌感染后使用伏立康唑治疗的情况,同时与相似患者使用脂质体两性霉素B的情况进行对照,并进行文献复习。方法50例患者使用伏立康唑治疗,57例患者使用两性霉素B治疗,根据患者临床表现及CT变化判断疗效。结果伏立康唑组患者有效40例,大多数患者耐受良好;两性霉素B组有效37例,患者耐受较差,甚至无法继续治疗。结论伏立康唑可替代两性霉素B有效用于恶性血液病患者真菌感染的治疗。
Objective To investigate the use of voriconazole for the treatment of patients with hematologic malignancies after fungal infection and to compare the use of liposomal amphotericin B with similar patients and to review the literature. Methods Fifty patients were treated with voriconazole, 57 patients were treated with amphotericin B, and the therapeutic effect was judged according to the clinical manifestations and CT changes. Results Voriconazole group of 40 patients effective, most patients were well tolerated; amphotericin B group of 37 patients effective, patients with poor tolerance, or even unable to continue treatment. Conclusion Voriconazole can be used as an alternative to amphotericin B for the treatment of fungal infections in patients with hematologic malignancies.